Drug-eluting/biodegradable stents - 26/10/11
Doi : 10.1016/j.gie.2011.07.028
ASGE Technology Committee
Jeffrey L. Tokar, MD, Subhas Banerjee, MD, Bradley A. Barth, MD : NASPGHAN representative, David J. Desilets, MD, Vivek Kaul, MD, Sripathi R. Kethi, MD, Marcos C. Pedrosa, MD, Patrick R. Pfau, MD, Douglas K. Pleskow, MD, Shyam Varadarajulu, MD, Amy Wang, MD, Louis-Michel Wong Kee Song, MD, Sarah A. Rodriguez, MD : Committee ChairAbbreviations : ASGE, ESD, SEMS
Plan
| DISCLOSURE: J. Tokar is a consultant for Boston Scientific and is a speaker for and recipient of an educational grant from Fujinon. D. Pleskow is a consultant for Boston Scientific and is on the medical advisory board of Beacon Endoscopic. L.M. Wong Kee Song has received research support from Olympus and Fujinon. No other financial relationships relevant to this publication were disclosed. |
© 2011
Publié par Elsevier Masson SAS.
Vol 74 - N° 5
P. 954-958 - novembre 2011 Retour au numéro
Article précédent
- A pathway to endoscopic bariatric therapies
- ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy, Gregory G. Ginsberg, Bipan Chand, Gregory A. Cote, Ramsey M. Dallal, Steven A. Edmundowicz, Ninh T. Nguyen, Aurora Pryor, Christopher C. Thompson
- Emmet B. Keeffe, MD
- Aijaz Ahmed, Carlos O. Esquivel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?